
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 8, 2026

BONE BIOLOGICS CORPORATION

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

001-40899
(Commission
File Number)

42-1743430
(IRS Employer
Identification No.)

2 Burlington Woods Drive, Ste. 100
Burlington, MA
(Address of principal executive offices)

01803
(Zip Code)

Registrant's telephone number, including area code: **(781) 552-4452**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

<u>Title of each class</u>	<u>Trading Symbol(s)</u>	<u>Name of each exchange on which registered</u>
Common Stock, par value \$0.001 per share	BBLG	Nasdaq Capital Market
Warrants to Purchase Common Stock, par value \$0.001 per share	BBLGW	Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 7.01 Regulation FD Disclosure.

On January 8, 2026, Bone Biologics Corporation (the “Company”) issued a press release summarizing the corporate, scientific and operational milestones achieved during 2025 and outlining its strategic outlook for 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information furnished pursuant to this Item 7.01, including Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under such section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act.

Item 9.01 Financial Statements and Exhibits.

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release, dated January 8, 2026
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BONE BIOLOGICS CORPORATION

Date: January 8, 2026

By: */s/ Jeffrey Frelick*

Jeffrey Frelick

Chief Executive Officer



Bone Biologics Highlights 2025 Key Operational, Scientific, and Corporate Milestones and Provides 2026 Outlook

Key accomplishments include expanded rhNELL-1 shelf life, advanced NB1 development, strengthened balance sheet, and maintained Nasdaq compliance

BURLINGTON, Mass., January 8, 2026—(BUSINESS WIRE)—Bone Biologics Corporation (“Bone Biologics” or the “Company”) (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today summarized key corporate, scientific, and operational milestones achieved during 2025 and outlined its strategic outlook for 2026.

“We executed with discipline throughout 2025 as we focused on strengthening the foundation required to advance our clinical program,” stated Bone Biologics CEO Jeff Frelick. “During the year, we made meaningful progress across product readiness, intellectual property, and capital structure, including extending the validated shelf life of our rhNELL-1 protein and completing financings that position us to continue advancing NB1. As we enter 2026, our goal remains the thoughtful progression of our clinical development efforts while maintaining capital discipline and creating long-term value for all our stakeholders.”

2025 Highlights

The Company focused on executing against its strategic priorities across development, operations, and corporate governance. The milestones below reflect the Company’s efforts to support ongoing program, maintain organizational stability, and position the business for future advancement.

- **Extended rhNELL-1 Product Shelf Life** — In December 2025, the Company announced the successful extension of the validated shelf life of its lead rhNELL-1 protein product candidate to 24 months, advancing prior 12- and 18-month stability milestones. This improvement supports manufacturing efficiency, supply-chain flexibility, and clinical readiness
 - **Strengthened Capital Position** — Bone Biologics completed a registered public offering for total gross proceeds of \$5 million during the second quarter of 2025, providing funding to support ongoing clinical development activities, intellectual property initiatives, and general corporate purposes
 - **Expanded Intellectual Property Portfolio** — The Company filed a U.S. patent application related to its bone regeneration technology based on recombinant human NELL-1, further strengthening its proprietary platform
 - **Maintained Nasdaq Listing Compliance** — In June 2025, Bone Biologics regained compliance with Nasdaq’s minimum bid price requirement, reinforcing its continued access to the public capital markets
 - **Increased Investor Engagement** — Management participated in the H.C. Wainwright 27th Annual Global Investment Conference and issued a detailed stockholder letter outlining progress across the Company’s clinical and operational initiatives
-

Outlook for 2026

As the Company enters 2026, it plans to remain focused on advancing its clinical-stage program and strengthening its operational foundation:

- **Clinical Development Progression** — Continuing advancement of NB1, the Company’s rhNELL-1-based bone graft product candidate, including the expected completion of patient enrollment in its first-in-human clinical trial and potential interim updates, as appropriate
- **Operational and Manufacturing Execution** — Ongoing efforts to support regulatory readiness and future commercialization planning
- **Intellectual Property Strategy** — Continuing pursuit of relevant patent protections to enhance long-term platform value
- **Financial Discipline and Strategic Focus** — Maintaining prudent capital management while supporting scientific progress and shareholder engagement

About Bone Biologics

Bone Biologics was founded to pursue regenerative medicine for bone. The Company is undertaking work with select strategic partners that builds on the preclinical research of the NELL-1 protein. Bone Biologics is focusing development efforts for its bone graft substitute product on bone regeneration in spinal fusion procedures, while additionally having rights to trauma and osteoporosis applications. For more information, please visit www.bonebiologics.com.

Forward-Looking Statements

Certain statements contained in this press release, including, without limitation, statements regarding the Company’s strategic outlook and expected achievements for the year 2026, timing, implementation, and success of the Company’s pilot clinical study, the Company’s development of rhNELL-1 and achievement of operational milestones, the ability of the Company’s lead product candidate NB1 to provide rapid, specific and guided control over bone regeneration and show fusion success in humans, the ability of NB1 to compete in global markets, the Company’s performance as a public company, as well as statements containing the words “anticipate,” “may,” “believe,” “continue,” “goal,” “plan,” “expect,” “outlook,” and words of similar import, constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company’s actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including, but not limited to, market and other conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 and the Company’s other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.

Contacts

CORE IR

(212) 655-0924

investors@bonebiologics.com
